At a glance
ClinicalIndex Comparison RecordN/ACompleted· 38,499 enrolled
Drug / intervention
Observationaldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Comparative Safety and Effectiveness of Warfarin and Dabigatran Utilized in the Humana Non-Valvular Atrial Fibrillation (NVAF) Patient Population-A Retrospective Database Analysis
In Brief
An observational study evaluating Observational for Atrial Fibrillation. Completed, enrolled 38,499 participants across 1 site.
Detailed Summary
This study is an opportunity for Boehringer Ingelheim to collaborate with Humana to conduct comparative safety and effectiveness studies of dabigatran and warfarin using real world data from Humana's health plan operations.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 2014
Enrollment StartOct 2014
Primary CompletionMar 2016
TodayJul 2026
First PostedFeb 13, 2014
Enrollment StartOct 28, 2014
Primary CompletionMar 15, 2016
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 12.4 years ago
Interventions
Observationaldrug
Retrospective Chart Review